EU nod for Sandoz’ Remicade biosimilar Zessly

Consumer

Sandoz have been given approval from the European Commission for use of its reference medicine Zessly, which blocks the action of tumour necrosis factor. The drug has followed a comprehensive development programme and according to the head of speciality at Sandoz UK, using Biosimilars “has saved the NHS £170 million.”

“The European Commission has green-lighted Novartis unit Sandoz' Zessly, a biosimilar version of Johnson & Johnson and Merck's Remicade.“

The head of speciality also added “The NHS has moved quickly to achieve these savings and has become an example for healthcare systems across the world in the adoption of biosimilar medicines. We look forward to bringing Zessly to all patients who can benefit from this therapy,”

See all the latest jobs in Consumer
Return to news